Metacrine, Inc.
Metacrine, Inc. (MTCR): 1 pipeline candidate · ~57 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
57.3 months
0% dilution
Lead: Phase 2
1 candidate
N/A
N/A
A transparent, data-derived signal for Metacrine, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$52.8M
Quarterly Burn
$2.8M
Runway
57.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| met642 | Phase 2 |
Frequently asked questions
How many drug candidates are in Metacrine, Inc.'s pipeline?
Metacrine, Inc. (MTCR) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Metacrine, Inc.'s lead drug candidate?
Metacrine, Inc.'s most advanced tracked candidate is met642 (Phase 2) for Ulcerative Colitis (UC).
What is Metacrine, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Metacrine, Inc. has approximately 57.3 months of cash runway.
Get the full picture on Metacrine, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.